Product Description
Mechanisms of Action: IL6 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Arthritis, Rheumatoid|Lupus Erythematosus, Systemic
Phase 1: Arthritis, Rheumatoid
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2014-003034-42 | P2 |
Completed |
Arthritis, Rheumatoid |
2018-08-14 |
|
ALX0061-C203 | P2 |
Completed |
Arthritis, Rheumatoid |
2018-08-01 |
|
STEADY | P2 |
Completed |
Lupus Erythematosus, Systemic |
2018-01-16 |
|
ALX0061-C204 | P2 |
Completed |
Lupus Erythematosus, Systemic |
2018-01-01 |